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Abstract  
 
Background: Pneumonia treatment decisions are often guided by the use of severity assessment 
scores, such as the well-known and validated pneumonia severity index and CURB-65. Several 
pneumonia severity scoring systems have been developed, but the evidence of their utilisation in low- 
and middle-income countries (LMICs) remains limited. 
Objective: In this review, we sought to systematically investigate the evidence around the validity and 
performance of the existing pneumonia severity scores in adult patients diagnosed with community-
acquired pneumonia in LMICs.  
Methods: Medline (Ovid), Embase (Ovid), Cochrane Central Register of Controlled Trials, Scopus, and 
Web of Science were searched for eligible articles up to May 2020. Relevant data were extracted from 
the included studies. The association between high severity scores and the studied outcome was 
tested. Pooled estimates of the severity scores performance (sensitivity and specificity) at their high-
risk cutoffs in predicting the reported outcome were estimated using the bivariate meta-analysis model. 
Heterogeneity was assessed using the I² index. 
Results: Overall, 11 studies met our inclusion criteria, of which, only six with sufficient data were 
included in the final meta-analysis that involved examining CURB-65 and CRB-65 scores. Both scores 
at a threshold ≥3 were related to an increased mortality risk, with pooled relative risks of 8.58 (95%CI: 
3.48-21.18) and 4.83 (95%CI: 2.52-9.28) for CURB-65 and CRB-65, respectively. The predictive 
performance of CURB-65 and CRB-65 at their high-risk cutoffs, respectively, were as follows: the 
pooled sensitivity, 0.69 (95%CI: 0.25-0.94) and 0.04 (95%CI: 0.00-0.40); the pooled specificity, 0.89 
(95%CI: 0.72-0.96) and 0.99 (95%C%: 0.95-1.00); and the area under the summary receiver operator 
characteristic curves, 0.90 (95%CI: 0.87-0.92) and 0.86 (95%CI: 0.83-0.89). 
Conclusion: CURB-65 and CRB-65 at a cutoff ≥3 are strongly associated with mortality and appear to 
be valid scores for mortality prediction in LMICs. CURB-65 exhibited higher sensitivity and overall 
accuracy, compared to CRB-65. 
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